Connect with us

Headlines

Eye Health Firm Gets FDA Warning Letter

mm

Published

on

The company ‘takes the warning letter seriously.’

BEDFORD, MA — Ocular Therapeutix Inc., a biopharmaceutical company focused on eye conditions, announced the receipt of a warning letter from the U.S. Food and Drug Administration dated Oct. 17.

The letter relates to Ocular’s compliance with data collection and information reporting obligations, according to a press release from the company. The study is required for approval of ReSure Sealant. The company is required to provide periodic reports to the FDA on the progress of the post-approval study until it is completed.

The company said it will respond to the letter within the required 15-day period.

“Ocular Therapeutix takes the warning letter seriously and is committed to working with the FDA to address and resolve the concerns cited in the warning letter,” according to the release.

Advertisement

ReSure Sealant, a hydrogel ophthalmic wound sealant, is described as “a product currently indicated for intraoperative management of clear corneal incisions (up to 3.5mm) with a demonstrated wound leak for which a temporary dry surface can be achieved, in order to prevent postoperative fluid egress from such incisions following cataract surgery with intraocular lens placement in adults.”

SPONSORED VIDEO

Shamir Glacier Plus Metaform: Stronger. Thinner. Lighter.

It’s time for a new compromise-free lens technology that completely changes our concept of what's possible. Glacier Plus™ Metaform enables customers to enjoy strength and safety alongside the aesthetics of thin and light lenses. Now Available: The next technical revolution in the world of optics.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular